Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a targeted drug keep hodgkin lymphoma away after transplant?

NCT ID NCT05100056

Disease control Sponsor: Takeda Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is checking how well the drug brentuximab vedotin works for adults with Hodgkin lymphoma who have had a stem cell transplant. Researchers will track 70 participants for about 2 years to see if the drug helps prevent the cancer from coming back. It is an observational study, meaning the drug is given as part of normal care, not as an experiment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
brentuximab vedotin
What this could lead to
If successful, this study could confirm that brentuximab vedotin helps keep Hodgkin lymphoma from returning after a stem cell transplant.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It is small (70 people) and only follows patients for about 2 years, so long-term benefits or risks are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2022

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants diagnosed with HL (previously enrolled in BV HL NDP) who underwent or are candidates for ASCT will be enrolled in this study.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1\. Adult participant (aged greater than or equal to \[\>=18\] years) that underwent or are candidates for ASCT and were enrolled in BV HL NDP receiving treatment according to the Summary of Product Characteristics for Adcetris and NDP. Exclusion Criteria: 1. Currently participates or plans to participate in any interventional clinical trial. 2. Any other reason that, in the Investigator's opinion, makes the participant unsuitable to participate in this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hodgkin lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Hodgkins lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hodgkin lymphoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    13 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Centrum Onkologii Ziemi Lubelskiej im. sw. Jana z Dukli

    RECRUITING

    Lublin, Lublin Voivodeship, 20-090, Poland

  • Instytut Hematologii i Transfuzjologii

    RECRUITING

    Warsaw, Masovian Voivodeship, 02-776, Poland

  • NU-MED Specjalistyczny Szpital Onkologiczny Tomaszow Mazowiecki

    RECRUITING

    Tomaszow Mazowiecki, Masovian Voivodeship, 97-200, Poland

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy

    RECRUITING

    Warsaw, Masovian Voivodeship, 02-781, Poland

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy Oddzial w Krakowie

    RECRUITING

    Krakow, Lesser Poland Voivodeship, 31-115, Poland

  • Samodzielny Publiczny Szpital Kliniczny im. Andrzeja Mieleckiego Slskiego Uniwersytetu Medycznego w Katowicach

    RECRUITING

    Katowice, Slskie, 40-027, Poland

  • Samodzielny Publiczny Zaklad Opieki Zdrowotnej MSWiA z Warminsko - Mazurskim Centrum Onkologii w Olsztynie

    RECRUITING

    Olsztyn, Warmian-Masurian Voivodeship, 10-228, Poland

  • Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie

    RECRUITING

    Krakow, Lesser Poland Voivodeship, 31-501, Poland

  • Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu

    RECRUITING

    Poznan, Greater Poland Voivodeship, 61-848, Poland

  • Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu

    RECRUITING

    Wroclaw, Dolnoslskie, 50-556, Poland

  • Uniwersyteckie Centrum Kliniczne WUM

    RECRUITING

    Warsaw, Masovian Voivodeship, 02-097, Poland

  • Uniwersyteckie Centrum Kliniczne, Gdansk

    RECRUITING

    Gdansk, Pomeranian Voivodeship, 80-214, Poland

    Contact Email: •••••@•••••

  • Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii, im. M. Kopernika w Lodzi

    RECRUITING

    Lodz, Łódź Voivodeship, 93-513, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.